Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.4710
-0.0020 (-0.42%)
Jun 26, 2026, 5:15 PM CET
Prostatype Genomics AB Market Cap
Prostatype Genomics AB has a market cap or net worth of 27.88 million as of June 26, 2026. Its market cap has decreased by -33.68% in one year.
Market Cap
27.88M
Enterprise Value
24.11M
Revenue
594.00K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.47
Market Cap Chart
Since November 3, 2020, Prostatype Genomics AB's market cap has decreased from 92.30M to 27.88M, a decrease of -69.80%. That is a compound annual growth rate of -19.11%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 26, 2026 | 27.88M | 57.00% |
| Dec 30, 2025 | 17.76M | -76.14% |
| Dec 30, 2024 | 74.42M | 555.78% |
| Dec 29, 2023 | 11.35M | -76.58% |
| Dec 30, 2022 | 48.46M | -64.07% |
| Dec 30, 2021 | 134.89M | -28.46% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Nov 3, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Swedish Orphan Biovitrum AB | 161.23B |
| Getinge AB | 53.81B |
| Sectra AB | 52.75B |
| Medicover AB | 34.73B |
| Guard Therapeutics International AB | 35.09M |
| Perpetua Medical AB | 30.21M |
| Magle Chemoswed Holding AB | 28.48M |
| Aino Health AB | 26.18M |